Broad ChemoCentryx Inflammation Alliance Plants CEEDD Downstream
This article was originally published in Start Up
Executive SummaryChemoCentryx's broad deal with GSK's Center for Excellence in External Drug Discovery (CEEDD) moves CEEDD downstream into early clinical territory and sets the biotech up for a potential IPO. The deal also illustrates the difficulties in defining alliance parameters like proof-of-concept.
You may also be interested in...
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.